ArticleCureus2025
Ewing Sarcoma of the Maxilla: An Uncommon Anatomical Presentation in a Young Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ewing sarcoma (ES) of the maxilla is an exceptionally rare entity that can mimic odontogenic or inflammatory conditions, often resulting in diagnostic delay. We report the case of a 23-year-old female who presented with a painless, progressively enlarging swelling of the anterior maxilla. Imaging demonstrated an expansile osteolytic lesion with cortical disruption. Histopathologic evaluation revealed a small round cell neoplasm, and immunohistochemical analysis showed diffuse membranous expression of cluster of differentiation 99 (CD99) and focal nuclear positivity for Friend leukemia integration 1 (FLI-1), supporting the diagnosis within the ES family of tumors in the appropriate clinicoradiologic context. The patient underwent subtotal maxillectomy with intraoperative margin assessment, achieving complete surgical excision with histologically negative margins, followed by adjuvant chemotherapy with epirubicin, cisplatin, and ifosfamide, as well as localized radiotherapy. At 18 months of clinical and radiologic follow-up, there was no evidence of local recurrence, with preserved oral function and satisfactory aesthetic outcomes on clinical evaluation. This report highlights the importance of considering malignant small round cell tumors in rapidly enlarging maxillofacial lesions and emphasizes the role of multidisciplinary management in achieving sustained local disease control while preserving postoperative function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.